Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era Antiviral and monoclonal Antibodies in Haematological Patients in the omicron era
Main Article Content
Keywords
Abstract
Abstract: Im We describe here a single-center case series of 27 IC COVID-19 inpatients (mostly with haematological disorders) treated with a combined therapy based on tixagevimab/cilgavimab (T/C) plus small-molecule antivirals (AV), between April 1 2022 and November 30 2022.
Keywords: immunocompromised; SARS-CoV-2 infection; monoclonal antibodies; antivirals; persistent infection; viral evolution
Downloads
Download data is not yet available.
Abstract 872
PDF Downloads 726
HTML Downloads 27
References
1. Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z, et al. Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States. Emerg Infect Dis, 2020 Aug;26(8):1720-1730. doi: 10.3201/eid2608.191493.
2. https://ecpc.org/joint-statement-on-the-protection-of-immunocompromised-patients/, accessed on Jan 20, 2023
3. Suárez-García I, Perales-Fraile I, González-García A, Muñoz-Blanco A, Manzano L, Fabregate M, et al. In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. PLoS One, 2021 Aug 3;16(8):e0255524. doi: 10.1371/journal.pone.0255524.
4. Singson JRC, Kirley PD, Pham H, Rothrock G, Armistead I, Meek Jet al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep, 2022 Jul 8;71(27):878-884. doi: 10.15585/mmwr.mm7127a3.
5. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med, 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364.
6. D'Abramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C, et al. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Infect Dis, 2021 Jun;107:247-250. doi: 10.1016/j.ijid.2021.04.068.
7. Leung WF, Chorlton S, Tyson J, Al-Rawahi GN, Jassem AN, Prystajecky N, et al. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. Int J Infect Dis, 2022 Jan;114:178-182. doi: 10.1016/j.ijid.2021.10.045.
8. Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother, 2021 Feb;27(2):387-389. doi: 10.1016/j.jiac.2020.12.001.
9. DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity, 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006.
10. Ko KKK, Yingtaweesittikul H, Tan TT, Wijaya L, Cao DY, Goh SS, et al. Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. Microbiol Spectr, 2022 Jun 29;10(3):e0079122. doi: 10.1128/spectrum.00791-22.
11. D'Abramo A, Vita S, Nicastri E. Correction: The unmet need for COVID-19 treatment in immunocompromised patients. BMC Infect Dis. 2023 Jan 31;23(1):61. doi: 10.1186/s12879-023-08034-0. Erratum for: BMC Infect Dis, 2022 Dec 12;22(1):930.
12. Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, et al. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis, 2022 Oct 20;22(1):793. doi: 10.1186/s12879-022-07774-9. Erratum in: BMC Infect Dis. 2022 Nov 24;22(1):883.
13. D'Abramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E, et al. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. Front Immunol, 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339.
14. Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 2022 Oct;10(10):985-996.
15. Berno G, Fabeni L, Matusali G, Gruber CEM, Rueca M, Giombini E, Garbuglia AR. SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. Pathogens, 2022 Sep 17;11(9):1058. doi: 10.3390/pathogens11091058. PMID: 36145490; PMCID: PMC9504725
16. Rueca M, Giombini E, Messina F, Bartolini B, Di Caro A, Capobianchi MR, et al. The Easy-to-Use SARS-CoV-2 Assembler for Genome Sequencing: Development Study. JMIR Bioinform Biotech, 2022 Mar 14;3(1):e31536. doi: 10.2196/31536.
17. Fu L, NiuB, Zhu Z, Wu S, & Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. In Bioinformatics, 2012; (Vol. 28, Issue 23, pp. 3150–3152). Oxford University Press (OUP). https://doi.org/10.1093/bioinformatics/bts565
18. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol, 2015 Jan;32(1):268-74. doi: 10.1093/molbev/msu300. Epub 2014 Nov 3. PMID: 25371430; PMCID: PMC4271533.
19. Denkinger, C.M., Janssen, M., Schäkel, U. et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer, 4, 96–107 (2023).
20. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open, 2023;6(1):e2250647.
21. Vita S, Rosati S, Ascoli Bartoli T, Beccacece A, D'Abramo A, Mariano A, et al. Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. Pathogens, 2022 Aug 5;11(8):882. doi: 10.3390/pathogens11080882
22. Juanola-Falgarona M, Peñarrubia L, Jiménez-Guzmán S, Porco R, Congost-Teixidor C, Varo-Velázquez M, et al. Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel. Int J Infect Dis, 2022 Sep;122:930-935. doi: 10.1016/j.ijid.2022.07.022.
23. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1. Erratum in: Nature. 2020 Dec;588(7839):E35.
24. https://covdb.stanford.edu/susceptibility-data/table-mab-susc/ Accessed on June 28, 2023
25. Hammarström L, Abolhassani H, Baldanti F, Marcotte H, Pan-Hammarström Q. Development of Passive Immunity Against SARS-CoV-2 for Management of Immunodeficient Patients—a Perspective. J Allergy Clin Immunol, 2020, 146:58–60. doi: 10.1016/j.jaci.2020.04.043
26. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol, 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x.
27. Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases, 2020 Oct 6;8(19):4280-4285. doi: 10.12998/wjcc.v8.i19.4280.
28. De Forni D, Poddesu B, Cugia G, Chafouleas J, Lisziewicz J, Lori F. Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. PLoS One, 2022 Nov 10;17(11):e0276751. doi: 10.1371/journal.pone.0276751.
29. Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol, 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0. PMID: 34649563; PMCID: PMC8515781.
30. Farroni C, Aiello A, Picchianti-Diamanti A, Laganà B, Petruccioli E, Agrati C, et al.. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. Int J Infect Dis, 2022 Dec;125:195-208. doi: 10.1016/j.ijid.2022.10.035. Epub 2022 Nov 1. PMID: 36328289; PMCID: PMC962202528.
31. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. Int J Mol Sci, 2021 Dec 21;23(1):29. doi: 10.3390/ijms23010029.
32. Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW; COVID-19 Genomics UK (COG-UK) Consortium et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol, 2023 Feb;21(2):112-124. doi: 10.1038/s41579-022-00809-7.
33. https://www.fda.gov/media/156152/download , last accessed October 9, 2023
34. Andrés C, González-Sánchez A, Jiménez M, Márquez-Algaba E, Piñana M, Fernández-Naval C, et al. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion. Clin Microbiol Infect, 2022 Sep 5:S1198-743X(22)00458-X. doi: 10.1016/j.cmi.2022.08.021. Epub ahead of print. PMID: 36067943.
2. https://ecpc.org/joint-statement-on-the-protection-of-immunocompromised-patients/, accessed on Jan 20, 2023
3. Suárez-García I, Perales-Fraile I, González-García A, Muñoz-Blanco A, Manzano L, Fabregate M, et al. In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. PLoS One, 2021 Aug 3;16(8):e0255524. doi: 10.1371/journal.pone.0255524.
4. Singson JRC, Kirley PD, Pham H, Rothrock G, Armistead I, Meek Jet al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep, 2022 Jul 8;71(27):878-884. doi: 10.15585/mmwr.mm7127a3.
5. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med, 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364.
6. D'Abramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C, et al. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. Int J Infect Dis, 2021 Jun;107:247-250. doi: 10.1016/j.ijid.2021.04.068.
7. Leung WF, Chorlton S, Tyson J, Al-Rawahi GN, Jassem AN, Prystajecky N, et al. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. Int J Infect Dis, 2022 Jan;114:178-182. doi: 10.1016/j.ijid.2021.10.045.
8. Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother, 2021 Feb;27(2):387-389. doi: 10.1016/j.jiac.2020.12.001.
9. DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity, 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006.
10. Ko KKK, Yingtaweesittikul H, Tan TT, Wijaya L, Cao DY, Goh SS, et al. Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. Microbiol Spectr, 2022 Jun 29;10(3):e0079122. doi: 10.1128/spectrum.00791-22.
11. D'Abramo A, Vita S, Nicastri E. Correction: The unmet need for COVID-19 treatment in immunocompromised patients. BMC Infect Dis. 2023 Jan 31;23(1):61. doi: 10.1186/s12879-023-08034-0. Erratum for: BMC Infect Dis, 2022 Dec 12;22(1):930.
12. Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, et al. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis, 2022 Oct 20;22(1):793. doi: 10.1186/s12879-022-07774-9. Erratum in: BMC Infect Dis. 2022 Nov 24;22(1):883.
13. D'Abramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E, et al. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. Front Immunol, 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339.
14. Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 2022 Oct;10(10):985-996.
15. Berno G, Fabeni L, Matusali G, Gruber CEM, Rueca M, Giombini E, Garbuglia AR. SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. Pathogens, 2022 Sep 17;11(9):1058. doi: 10.3390/pathogens11091058. PMID: 36145490; PMCID: PMC9504725
16. Rueca M, Giombini E, Messina F, Bartolini B, Di Caro A, Capobianchi MR, et al. The Easy-to-Use SARS-CoV-2 Assembler for Genome Sequencing: Development Study. JMIR Bioinform Biotech, 2022 Mar 14;3(1):e31536. doi: 10.2196/31536.
17. Fu L, NiuB, Zhu Z, Wu S, & Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. In Bioinformatics, 2012; (Vol. 28, Issue 23, pp. 3150–3152). Oxford University Press (OUP). https://doi.org/10.1093/bioinformatics/bts565
18. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol, 2015 Jan;32(1):268-74. doi: 10.1093/molbev/msu300. Epub 2014 Nov 3. PMID: 25371430; PMCID: PMC4271533.
19. Denkinger, C.M., Janssen, M., Schäkel, U. et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer, 4, 96–107 (2023).
20. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open, 2023;6(1):e2250647.
21. Vita S, Rosati S, Ascoli Bartoli T, Beccacece A, D'Abramo A, Mariano A, et al. Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. Pathogens, 2022 Aug 5;11(8):882. doi: 10.3390/pathogens11080882
22. Juanola-Falgarona M, Peñarrubia L, Jiménez-Guzmán S, Porco R, Congost-Teixidor C, Varo-Velázquez M, et al. Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel. Int J Infect Dis, 2022 Sep;122:930-935. doi: 10.1016/j.ijid.2022.07.022.
23. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1. Erratum in: Nature. 2020 Dec;588(7839):E35.
24. https://covdb.stanford.edu/susceptibility-data/table-mab-susc/ Accessed on June 28, 2023
25. Hammarström L, Abolhassani H, Baldanti F, Marcotte H, Pan-Hammarström Q. Development of Passive Immunity Against SARS-CoV-2 for Management of Immunodeficient Patients—a Perspective. J Allergy Clin Immunol, 2020, 146:58–60. doi: 10.1016/j.jaci.2020.04.043
26. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol, 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x.
27. Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases, 2020 Oct 6;8(19):4280-4285. doi: 10.12998/wjcc.v8.i19.4280.
28. De Forni D, Poddesu B, Cugia G, Chafouleas J, Lisziewicz J, Lori F. Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. PLoS One, 2022 Nov 10;17(11):e0276751. doi: 10.1371/journal.pone.0276751.
29. Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol, 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0. PMID: 34649563; PMCID: PMC8515781.
30. Farroni C, Aiello A, Picchianti-Diamanti A, Laganà B, Petruccioli E, Agrati C, et al.. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. Int J Infect Dis, 2022 Dec;125:195-208. doi: 10.1016/j.ijid.2022.10.035. Epub 2022 Nov 1. PMID: 36328289; PMCID: PMC962202528.
31. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. Int J Mol Sci, 2021 Dec 21;23(1):29. doi: 10.3390/ijms23010029.
32. Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW; COVID-19 Genomics UK (COG-UK) Consortium et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol, 2023 Feb;21(2):112-124. doi: 10.1038/s41579-022-00809-7.
33. https://www.fda.gov/media/156152/download , last accessed October 9, 2023
34. Andrés C, González-Sánchez A, Jiménez M, Márquez-Algaba E, Piñana M, Fernández-Naval C, et al. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion. Clin Microbiol Infect, 2022 Sep 5:S1198-743X(22)00458-X. doi: 10.1016/j.cmi.2022.08.021. Epub ahead of print. PMID: 36067943.
Article Sidebar
Published
Apr 30, 2024
Article Details
How to Cite
Vita, S. (2024) “Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era: Antiviral and monoclonal Antibodies in Haematological Patients in the omicron era”, Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024043. doi: 10.4084/MJHID.2024.043.
Section
Scientific Letters
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
Author Biography